COSTS-CONSEQUENCES ANALYSIS OF CEFTAROLINE FOSAMIL FOR THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

被引：0
|
作者：
Salgado, De Santana C. [1 ]
Holanda, P. [2 ]
Senna, T. [2 ]
Carmo, L. [2 ]
Alexandre, R. F. [2 ]
机构：
[1] Pfizer, Santos, SP, Brazil
[2] Pfizer, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN23
引用
收藏
页码：S109 / S109
页数：1
相关论文
共 50 条
  • [41] Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis
    Hagberg, L
    Carbon, C
    Van Rensburg, DJ
    Fogarty, C
    Dunbar, L
    Pullman, J
    RESPIRATORY MEDICINE, 2003, 97 (06) : 625 - 633
  • [42] Pharmacoeconomic analysis of severe community-acquired pneumonia treatment
    Kulikov, A.
    Krysanov, I
    VALUE IN HEALTH, 2007, 10 (03) : A165 - A165
  • [43] PHARMACOECONOMIC ANALYSIS OF TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA (CAP)
    Zaitsev, A.
    Synopalnikov, A.
    Tyrsin, O.
    VALUE IN HEALTH, 2011, 14 (07) : A278 - A278
  • [44] PROBABILITY OF PK/PD TARGET ATTAINMENT (PTA) FOR ASIAN PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP) TREATED WITH CEFTAROLINE FOSAMIL (CPT-F).
    Li, J.
    Melnick, D. A.
    Ambler, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S44 - S44
  • [45] Efficacy and Safety of Ceftaroline for the Treatment of Community-Acquired Pneumonia: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
    Lan, Shao-Huan
    Chang, Shen-Peng
    Lai, Chih-Cheng
    Lu, Li-Chin
    Chao, Chien-Ming
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (06)
  • [46] FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia
    Low, Donald E.
    File, Thomas M., Jr.
    Eckburg, Paul B.
    Talbot, George H.
    Friedland, H. David
    Lee, Jon
    Llorens, Lily
    Critchley, Ian A.
    Thye, Dirk A.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 : III33 - III44
  • [47] Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function
    Canut, A.
    Isla, A.
    Rodriguez-Gascon, A.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2015, 45 (04) : 399 - 405
  • [48] Fluoroquinolone treatment of community-acquired pneumonia: A meta-analysis
    Salkind, AR
    Cuddy, PG
    Foxworth, JW
    ANNALS OF PHARMACOTHERAPY, 2002, 36 (12) : 1938 - 1943
  • [49] COST-EFFECTIVENESS ANALYSIS OF COMMUNITY-ACQUIRED PNEUMONIA TREATMENT
    Zaytsev, A.
    Makarevich, A.
    Kondratyeva, T.
    VALUE IN HEALTH, 2014, 17 (07) : A596 - A596
  • [50] FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia
    File, Thomas M., Jr.
    Low, Donald E.
    Eckburg, Paul B.
    Talbot, George H.
    Friedland, H. David
    Lee, Jon
    Llorens, Lily
    Critchley, Ian A.
    Thye, Dirk A.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 : III19 - III32
12345